Property developer China Vanke's Hong Kong shares firmed on Tuesday following a change of top management that reinforced government support for the company to contain its liquidity risks. State-backed China Vanke said on Monday that Chairman Yu Liang and CEO Zhu Jiusheng have stepped down,

Troubles at Vanke raise questions about the continued spread of the property crisis and whether the Chinese state will step in.

Property developer China Vanke on Monday said its chairman Yu Liang and CEO Zhu Jiusheng had resigned, amid concerns over the company's liquidity as

China Vanke Co’s chairman and chief executive officer will both resign in an abrupt move after the embattled developer warned of a record 45 billion yuan ($8.34 billion) loss for 2024.

The historic legislation for Basic Law Article 23, aimed at safeguarding national security and ensuring Hong Kong's stability and development, has topped a list of the ten most significant policies by the Hong Kong Special Administrative Region (HKSAR) government in 2024.

Currency traders looking for their next big idea could do worse than talk to Wong, who runs a news stand in Hong Kong’s Central District.

This is CNBC's live blog covering Asia-Pacific markets. Asia-Pacific markets rose Monday, ahead of Donald Trump's presidential inauguration as investors awaited greater clarity on the policies of the incoming U.S. administration. Hong Kong's Hang Seng ...

The Company makes available through the Investor Relations section of its internet website at http://ir.yumchina.com its filings with the HKEX as soon as reasonably practicable after electronically filing such materials with the HKEX. These filings may also be obtained by visiting the HKEX's website at http://www.hkex.com.hk.

The Chinese government is trying to encourage people to spend more by ensuring that share prices will rise, ordering pensions and mutual funds to invest more in domestic stocks to help jolt its languid markets out of the doldrums.

U.S.-based Prolium Biosciences has now agreed to pay InnoCare and Keymed $17.5 million in upfront and near-term payments to develop and commercialize ICP-B02 as a cancer drug outside of China. Prolium also has the right to develop ICP-B02 in non-cancer indications globally, according to a filling with the Hong Kong Stock Exchange (PDF).

In currencies, the dollar jumped 0.3% against the Chinese yuan in offshore trading, and rallied 0.4% versus the Aussie and 0.5% versus the New Zealand dollar, with the antipodean currencies tending to act as more liquid proxies for China's currency due to close trade ties.

New York leads the list, with London in second place and Hong Kong in third in the Global Financial Centres Index.